Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation

摘要

BackgroundLipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammatory biomarker, which is useful as an adjunct identification tool for cardiovascular disease. However, the important limitation of the conventional enzyme-linked immunosorbent assay (PLAC ELISA) for Lp-PLA2assay is its relatively low sensitivity and time consuming. A method to measure the Lp-PLA2simply, rapidly and sensitively is essential for predicting cardiovascular events in clinic. MethodsWe took advantage of magnetic separation integrated with chemiluminescence to detect Lp-PLA2. The concentration of Lp-PLA2was measured through a one-step process by mixing antibody labelled magnetic beads, antigen and antibody at one time. ResultsOur method realized the sample to answer within 17?min. The detection limit and measurement range were 0.18?ng/ml and 0.18–1350?ng/ml, respectively. The specificity assay showed that no appreciable interference was observed for the substances of bilirubin, triglyceride, hemoglobin, rheumatoid factor and human anti-mouse antibody up to the concentrations of 40?mg/dl, 1000?mg/dl, 2000?mg/dl, 1500?IU/ml and 30?ng/ml, separately. We also tested 122 clinical samples using our method, presenting good overall correlations (R2?=?0.979) to the PLAC ELISA. It is worth mentioning that, our method was faster, had a wider range of measurement and higher sensitivity compared with the PLAC ELISA. ConclusionsThe Lp-PLA2assay is straightforward, sensitive and precise, which is highly suitable to further explore the clinical performance of Lp-PLA2in studies of cardiovascular risk management.